Search company, investor...

Predict your next investment

Venture Capital
digitalisventures.com

Investments

53

Portfolio Exits

2

Funds

4

About Digitalis Ventures

Digitalis Ventures is a venture capital firm focused on investing in seed- and venture-stage companies building technology-enabled solutions to complex problems particularly in the area of human health. Digitalis Ventures (f/k/a Mars Ventures) spun out of Mars, Inc. in February 2016. Digitalis Ventures maintains a strategic affiliation with Mars allowing portfolio companies exposure to the global food giant.

Headquarters Location

640 Eighth Avenue 15th Floor, Suite A

New York, New York, 10036,

United States

Want to inform investors similar to Digitalis Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Digitalis Ventures News

EpiBiologics: Protein Degradation Platform Company Closes Over $70 Million

Aug 3, 2023

EpiBiologics – a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets – recently announced the company brought the total series A round to $73 million with the addition of $23 million from new investors Digitalis Ventures, Taiho Ventures, and existing investor Codon Capital. And in March, EpiBiologics launched its $50 million series A financing with participation from Mubadala Capital, Polaris Partners, Vivo Capital, and GV. The company also announced that Ann Lee-Karlon, Ph.D., will join as Chief Executive Officer, President, and member of the Board of Directors. And Dr. Lee-Karlon will focus on expanding EpiBiologics’ proprietary EpiTAC platform, establishing value-driven collaborations, and building the company’s bispecific antibody protein degrader therapeutics pipeline. Prior to EpiBiologics, Dr. Lee-Karlon served as Chief Operating Officer of Altos Labs. And she joined Altos at its initiation in 2021 and was instrumental in building the foundation for rapid growth to 500 employees across three global sites. Before Altos, Dr. Lee-Karlon spent over 18 years at Genentech, most recently as Senior Vice President. During her tenure at Genentech, she led portfolio strategy and operations and oversaw project leadership for over 80 drug development teams from research and development through FDA approval and global launch. She led major corporate partnerships and programs, including Ocrevus for multiple sclerosis and Rituxan in immunology. Dr. Lee-Karlon holds a B.S. in bioengineering from UC Berkeley, an MBA from Stanford University, and a Ph.D. in bioengineering from UC San Diego, where she was a National Science Foundation Fellow. The company welcomes new members to its board of directors, including Samuel Bjork, partner at Digitalis Ventures, and Seiji Miyahara, Ph.D., senior investment director at Taiho Ventures. Board member Mitchell Mutz, Ph.D., of Vivo Capital, who led the company’s efforts to close the series A extension, will continue as the CFO of EpiBiologics. KEY QUOTES: “I had the pleasure of working with Ann at Genentech and am confident her deep experience building therapeutic pipelines and leading strategic collaborations will be invaluable as EpiBiologics progresses novel protein degrader therapeutics toward the clinic. We would like to thank Rami Hannoush for his leadership as co-founder and interim CEO and look forward to an exciting next stage of growth for EpiBiologics under Ann’s leadership.” — David Schenkein, MD, general partner at GV “EpiBiologics has developed a groundbreaking platform to target membrane and extracellular proteins, leveraging a novel atlas of tissue-specific degrader antibodies. Targeted extracellular protein degradation represents a new therapeutic modality with a wide range of applications, including cancer, immunology, and neurological diseases. I’m excited to work with the outstanding scientific team, advisors, and leaders to deliver new and important treatment options for patients in need.” — Dr. Lee-Karlon, CEO of EpiBiologics “EpiBiologics has made tremendous progress with its leading-edge EpiTAC platform, which will unravel the underlying intricacies of disease biology to build precision therapeutics. We are excited to work closely with Ann as the new CEO and the entire EpiBiologics team to bring the next generation of medicines to patients.” — Samuel Bjork, partner at Digitalis Ventures “With Ann’s strong track record in the biopharma industry, we are thrilled to join EpiBiologics’ syndicate of investors. We look forward to helping EpiBiologics continue to develop its novel bispecific antibody platform towards important treatments for a broad range of diseases.” — Dr. Seiji Miyahara

Digitalis Ventures Investments

53 Investments

Digitalis Ventures has made 53 investments. Their latest investment was in EpiBiologics as part of their Series A - II on July 7, 2023.

CBI Logo

Digitalis Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/20/2023

Series A - II

EpiBiologics

$23M

Yes

1

4/12/2023

Seed VC - II

Companion

$6M

Yes

2

3/14/2023

Series B

Switch Therapeutics

$52M

Yes

5

3/1/2023

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/5/2023

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/20/2023

4/12/2023

3/14/2023

3/1/2023

1/5/2023

Round

Series A - II

Seed VC - II

Series B

Series A

Series A

Company

EpiBiologics

Companion

Switch Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$23M

$6M

$52M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

5

10

10

Digitalis Ventures Portfolio Exits

2 Portfolio Exits

Digitalis Ventures has 2 portfolio exits. Their latest portfolio exit was PetMedix on September 25, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/25/2023

Acquired

$99M

2

9/7/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/25/2023

9/7/2022

Exit

Acquired

Acquired

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

2

10

Digitalis Ventures Fund History

4 Fund Histories

Digitalis Ventures has 4 funds, including Digitalis Ventures Fund IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/19/2022

Digitalis Ventures Fund IV

$300M

1

3/9/2018

Companion Fund

Subscribe to see more

Subscribe to see more

$99M

10

1/4/2017

Digitalis Ventures Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Digitalis Seed Fund

10

Closing Date

10/19/2022

3/9/2018

1/4/2017

Fund

Digitalis Ventures Fund IV

Companion Fund

Digitalis Ventures Fund I

Digitalis Seed Fund

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$300M

$99M

$99M

Sources

1

10

10

10

Digitalis Ventures Team

1 Team Member

Digitalis Ventures has 1 team member, including current Managing Partner, Geoffrey W. Smith.

Name

Work History

Title

Status

Geoffrey W. Smith

Managing Partner

Current

Name

Geoffrey W. Smith

Work History

Title

Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.